Pyrotinib
- Generic Name
- Pyrotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H31ClN6O3
- CAS Number
- 1269662-73-8
- Unique Ingredient Identifier
- CJN36EQM0H
- Background
Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 151
- Registration Number
- NCT04447118
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
🇧🇪Antwerp University Hospital (UZA), Edegem, Belgium
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 216
- Registration Number
- NCT04398914
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2021-07-15
- Target Recruit Count
- 40
- Registration Number
- NCT04380012
- Locations
- 🇨🇳
The Second Affiliated hospital of Zhejiang University School of Medical, Hangzhou, Zhejiang, China
Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 97
- Registration Number
- NCT04367090
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 319
- Registration Number
- NCT04355858
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT04293276
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 280
- Registration Number
- NCT04290793
Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 316
- Registration Number
- NCT04254263
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 27
- Registration Number
- NCT04255056
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT04236310
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.